Emergence of pristinamycin resistance in India

Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Keshari, Shyam Sunder, Kapoor, Arun Kumar, Kastury, Nira, Singh, Dharmendra Kumar, Bhargava, Anudita
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825015/
https://www.ncbi.nlm.nih.gov/pubmed/20177582
http://dx.doi.org/10.4103/0253-7613.48884
_version_ 1782177774891433984
author Keshari, Shyam Sunder
Kapoor, Arun Kumar
Kastury, Nira
Singh, Dharmendra Kumar
Bhargava, Anudita
author_facet Keshari, Shyam Sunder
Kapoor, Arun Kumar
Kastury, Nira
Singh, Dharmendra Kumar
Bhargava, Anudita
author_sort Keshari, Shyam Sunder
collection PubMed
description Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 μg and 25 μg, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.
format Text
id pubmed-2825015
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-28250152010-02-22 Emergence of pristinamycin resistance in India Keshari, Shyam Sunder Kapoor, Arun Kumar Kastury, Nira Singh, Dharmendra Kumar Bhargava, Anudita Indian J Pharmacol Case Report Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 μg and 25 μg, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated. Medknow Publications 2009-02 /pmc/articles/PMC2825015/ /pubmed/20177582 http://dx.doi.org/10.4103/0253-7613.48884 Text en © Indian Journal of Pharmacology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Keshari, Shyam Sunder
Kapoor, Arun Kumar
Kastury, Nira
Singh, Dharmendra Kumar
Bhargava, Anudita
Emergence of pristinamycin resistance in India
title Emergence of pristinamycin resistance in India
title_full Emergence of pristinamycin resistance in India
title_fullStr Emergence of pristinamycin resistance in India
title_full_unstemmed Emergence of pristinamycin resistance in India
title_short Emergence of pristinamycin resistance in India
title_sort emergence of pristinamycin resistance in india
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825015/
https://www.ncbi.nlm.nih.gov/pubmed/20177582
http://dx.doi.org/10.4103/0253-7613.48884
work_keys_str_mv AT kesharishyamsunder emergenceofpristinamycinresistanceinindia
AT kapoorarunkumar emergenceofpristinamycinresistanceinindia
AT kasturynira emergenceofpristinamycinresistanceinindia
AT singhdharmendrakumar emergenceofpristinamycinresistanceinindia
AT bhargavaanudita emergenceofpristinamycinresistanceinindia

Ejemplares similares